CCN1 and acute lymphoblastic leukemia: Next, 4 primary T-ALL cells and 5 primary B-ALL cells (see Supplementary Table S3: P7-P15) were collected and exposed to recombinant human Cyr61; the results showed that recombinant human Cyr61 could also enhance primary ALL cell survival, and the anti-Cyr61 monoclonal antibody 093G9 could block this effect of Cyr61 on primary ALL cells (Fig. 2b, T-ALL p = 0.0035, *p < 0.05, B-ALL p = 0.0098, **p < 0.01, ANOVA with Student-Newman-Keuls tests).